CSIMarket



Best Performing Stocks In Healthcare Sector Over The Past 12 Months



 1 Day   Week  Current Month of July  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 
 

Shares fell by -2.73% on average, in Healthcare Sector over the past 12 months.

Here are the best performing stocks in Healthcare Sector.




BNTC

$9.22

$9.0170 4,441.87%
Last 12 Months


BNTC

$9.22

$9.0170 4,441.87%



Benitec Biopharma Inc

Benitec Biopharma Inc shares improved 4,441.87% over the past 12 months.


Benitec Biopharma Inc is a biotechnology company that focuses on developing and commercializing gene therapy products. They utilize their proprietary RNA interference technology to target and silence disease-causing genes, ultimately aiming to provide effective treatment options for various genetic diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 24.122 mill. $ - mill. $ -21.692 mill. 3 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 24.122 mill.


$ - mill.


$ -21.692 mill.

Employees Shares Outstanding P/E

-


3 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



VCNX

$7.1

$6.8100 2,348.28%
Last 12 Months


VCNX

$7.1

$6.8100 2,348.28%



Vaccinex Inc

Vaccinex Inc shares increased 2,348.28% over the past 12 months.


Vaccinex Inc operates on a biopharmaceutical business model, focusing on the development and commercialization of antibody-based therapies. The company utilizes its proprietary ActivMAb? Antibody Discovery Technology to discover and develop novel antibody therapeutics for the treatment of various diseases. Vaccinex collaborates with strategic partners and pharmaceutical companies to advance the clinical development and commercialization of its product candidates.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 31.999 mill. $ 0.795 mill. $ 2.765 mill. 5 mill. - Y/Y -60.00 %
Market Cap. Revenues TTM Net Income TTM

$ 31.999 mill.


$ 0.795 mill.


$ 2.765 mill.

Employees Shares Outstanding P/E

-


5 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -60.00 %


MRQ Y/Y - %



OCX

$3.21

$3.0000 1,428.57%
Last 12 Months


OCX

$3.21

$3.0000 1,428.57%



Oncocyte Corporation

Oncocyte Corporation shares increased 1,428.57% over the past 12 months.


Oncocyte Corporation is a healthcare company that specializes in developing and commercializing diagnostic tests aimed at improving cancer detection and treatment. They utilize cutting-edge technologies and collaborate with medical institutions to provide accurate and actionable information to healthcare providers, ultimately improving patient outcomes in the field of oncology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 26.527 mill. $ 1.343 mill. $ -12.943 mill. 8 mill. - Y/Y -96.31 %
Market Cap. Revenues TTM Net Income TTM

$ 26.527 mill.


$ 1.343 mill.


$ -12.943 mill.

Employees Shares Outstanding P/E

-


8 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -96.31 %


MRQ Y/Y - %



BACK

$1.49

$1.3819 1,278.35%
Last 12 Months


BACK

$1.49

$1.3819 1,278.35%



Imac Holdings Inc

Imac Holdings Inc stock went up 1,278.35% over the past 12 months.


IMAC Holdings Inc operates a network of integrated medical clinics that offer regenerative rehabilitation services and other medical treatments. The company generates revenue through direct patient care services and the sale of related medical products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.711 mill. $ - mill. $ -6.127 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.711 mill.


$ - mill.


$ -6.127 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



UPC

$3.71

$3.3443 914.49%
Last 12 Months


UPC

$3.71

$3.3443 914.49%



Universe Pharmaceuticals Inc

Universe Pharmaceuticals Inc shares increased 914.49% over the past 12 months.


Universe Pharmaceuticals Inc is a pharmaceutical company that follows a business model focused on research, development, and manufacturing of medications. They aim to identify and address unmet medical needs by developing innovative pharmaceutical products. Through strategic partnerships and collaborations, they strive to bring their products to market and provide effective healthcare solutions to patients worldwide.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 13.449 mill. $ 32.309 mill. $ -6.163 mill. 4 mill. - Y/Y -19.52 %
Market Cap. Revenues TTM Net Income TTM

$ 13.449 mill.


$ 32.309 mill.


$ -6.163 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -19.52 %


MRQ Y/Y - %



USNU

$0.75

$0.6600 733.33%
Last 12 Months


USNU

$0.75

$0.6600 733.33%



U s Neurosurgical Holdings Inc

U S Neurosurgical Holdings Inc stock increased 733.33% over the past 12 months.


U.S. Neurosurgical Holdings Inc. operates on a business model that focuses on providing highly specialized neurosurgical products and services. They emphasize innovation and research to develop cutting-edge medical devices and surgical techniques. Additionally, the company collaborates with healthcare professionals to offer training and education programs, enabling the adoption of their advanced neurosurgical solutions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 8.924 mill. $ - mill. $ -1.001 mill. 12 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 8.924 mill.


$ - mill.


$ -1.001 mill.

Employees Shares Outstanding P/E

-


12 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CRBP

$58

$50.8500 711.19%
Last 12 Months


CRBP

$58

$50.8500 711.19%



Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings Inc shares went up 711.19% over the past 12 months.


Corbus Pharmaceuticals Holdings Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for inflammatory and fibrotic diseases. Their business model revolves around conducting research and clinical trials to identify potential drug candidates, obtaining regulatory approvals, and subsequently commercializing these drugs to generate revenue. They aim to address unmet medical needs by creating and marketing novel treatments for diseases such as systemic sclerosis, cystic fibrosis, and other inflammatory conditions.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 256.570 mill. $ - mill. $ -47.461 mill. 4 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 256.570 mill.


$ - mill.


$ -47.461 mill.

Employees Shares Outstanding P/E

57


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CRIS

$6.49

$5.6598 681.74%
Last 12 Months


CRIS

$6.49

$5.6598 681.74%



Curis Inc

Curis Inc shares improved 681.74% over the past 12 months.


Curis Inc*s business model revolves around the development and commercialization of innovative cancer therapies. They focus on discovering and advancing drug candidates targeting specific molecular pathways involved in cancer growth and survival. The company collaborates with pharmaceutical partners to conduct clinical trials and seek regulatory approval for their products.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 37.535 mill. $ 9.812 mill. $ -47.730 mill. 6 mill. - Y/Y -9.19 %
Market Cap. Revenues TTM Net Income TTM

$ 37.535 mill.


$ 9.812 mill.


$ -47.730 mill.

Employees Shares Outstanding P/E

-


6 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -9.19 %


MRQ Y/Y - %



TIVC

$0.35

$0.3047 672.63%
Last 12 Months


TIVC

$0.35

$0.3047 672.63%



Tivic Health Systems Inc

Tivic Health Systems Inc stock went up 672.63% over the past 12 months.


Tivic Health Systems Inc is a company that operates on a direct-to-consumer business model. They develop and sell at-home medical devices for various health conditions, providing customers with the convenience of accessing healthcare solutions from the comfort of their own homes. By cutting out intermediaries and selling directly to consumers, Tivic Health Systems aims to deliver their products more efficiently and establish a direct relationship with their customers.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.416 mill. $ 1.331 mill. $ -9.139 mill. 1 mill. - Y/Y -40.88 %
Market Cap. Revenues TTM Net Income TTM

$ 0.416 mill.


$ 1.331 mill.


$ -9.139 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -40.88 %


MRQ Y/Y - %



EUDA

$4

$3.4209 590.73%
Last 12 Months


EUDA

$4

$3.4209 590.73%



Euda Health Holdings Limited

Euda Health Holdings Limited shares improved 590.73% over the past 12 months.


Euda Health Holdings Limited operates as a digital health platform that facilitates access to healthcare services. They offer a range of online health consultations and concierge services, enabling users to connect with healthcare professionals and receive personalized medical advice and treatment. Their business model focuses on leveraging technology to streamline the healthcare experience and improve access to quality care for individuals seeking medical assistance.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 80.767 mill. $ 11.244 mill. $ -27.358 mill. 20 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 80.767 mill.


$ 11.244 mill.


$ -27.358 mill.

Employees Shares Outstanding P/E

-


20 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



PRE

$5.32

$4.4862 538.04%
Last 12 Months


PRE

$5.32

$4.4862 538.04%



Prenetics Global Limited

Prenetics Global Limited shares increased 538.04% over the past 12 months.


Prenetics Global Limited is a company that operates in the field of personalized healthcare by offering genetic testing services to individuals. The company partners with healthcare providers and insurance companies to provide insights and recommendations based on genetic information, aiming to empower individuals to make informed decisions about their health.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 59.801 mill. $ 21.743 mill. $ -64.777 mill. 11 mill. - Y/Y -92.12 %
Market Cap. Revenues TTM Net Income TTM

$ 59.801 mill.


$ 21.743 mill.


$ -64.777 mill.

Employees Shares Outstanding P/E

1,035


11 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -92.12 %


MRQ Y/Y - %



MYO

$5.03

$4.2330 531.12%
Last 12 Months


MYO

$5.03

$4.2330 531.12%



Myomo Inc

Myomo Inc shares increased 531.12% over the past 12 months.


Myomo Inc*s business model revolves around the development and commercialization of advanced medical devices, specifically myoelectric orthotics for individuals with neuromuscular disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 177.390 mill. $ 17.258 mill. $ -7.855 mill. 35 mill. - Y/Y 13.12 %
Market Cap. Revenues TTM Net Income TTM

$ 177.390 mill.


$ 17.258 mill.


$ -7.855 mill.

Employees Shares Outstanding P/E

-


35 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 13.12 %


MRQ Y/Y - %



EDSA

$4.7499

$3.9224 474.01%
Last 12 Months


EDSA

$4.7499

$3.9224 474.01%



Edesa Biotech Inc

Edesa Biotech Inc shares improved 474.01% over the past 12 months.


Edesa Biotech Inc*s business model focuses on the development and commercialization of innovative therapeutics in the field of dermatology and gastrointestinal diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 15.165 mill. $ - mill. $ -7.245 mill. 3 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 15.165 mill.


$ - mill.


$ -7.245 mill.

Employees Shares Outstanding P/E

-


3 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



ELTP

$0.199

$0.1610 423.68%
Last 12 Months


ELTP

$0.199

$0.1610 423.68%



Elite Pharmaceuticals Inc

Elite Pharmaceuticals Inc stock went up 423.68% over the past 12 months.


Elite Pharmaceuticals Inc. is a pharmaceutical company that specializes in developing and manufacturing generic and abuse-deterrent controlled-release products. Their business model focuses on conducting research, obtaining regulatory approvals, and licensing their products to other pharmaceutical companies for commercialization and distribution.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 200.081 mill. $ 56.357 mill. $ 20.109 mill. 1,005 mill. 12.57 Y/Y 127.93 %
Market Cap. Revenues TTM Net Income TTM

$ 200.081 mill.


$ 56.357 mill.


$ 20.109 mill.

Employees Shares Outstanding P/E

67


1,005 mill.


12.57

Revenue Growth Income Growth

MRQ Y/Y 127.93 %


MRQ Y/Y - %



LBPH

$35.95

$28.6600 393.14%
Last 12 Months


LBPH

$35.95

$28.6600 393.14%



Longboard Pharmaceuticals Inc

Longboard Pharmaceuticals Inc stock increased 393.14% over the past 12 months.


Longboard Pharmaceuticals Inc is a biotechnology company focused on the discovery and development of therapies for neurological disorders. Their business model revolves around conducting comprehensive research, identifying promising drug candidates, and advancing them through preclinical and clinical trials. With a focus on innovative approaches and strategic partnerships, Longboard aims to ultimately bring safe and effective treatments to patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 844.374 mill. $ - mill. $ -50.734 mill. 23 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 844.374 mill.


$ - mill.


$ -50.734 mill.

Employees Shares Outstanding P/E

-


23 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



GOVX

$2.8

$2.2316 392.61%
Last 12 Months


GOVX

$2.8

$2.2316 392.61%



Geovax Labs Inc

Geovax Labs Inc stock increased 392.61% over the past 12 months.


Geovax Labs Inc*s business model primarily focuses on the development and commercialization of innovative vaccines to prevent and treat diseases, with a particular emphasis on HIV/AIDS. They aim to bridge the gap in preventing and managing these diseases through their vaccine candidates and strategic partnerships.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6.628 mill. $ - mill. $ -24.224 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 6.628 mill.


$ - mill.


$ -24.224 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



CADL

$6.01

$4.7314 370.05%
Last 12 Months


CADL

$6.01

$4.7314 370.05%



Candel Therapeutics Inc

Candel Therapeutics Inc shares improved 370.05% over the past 12 months.


Candel Therapeutics Inc*s business model is centered around developing and commercializing advanced biotherapeutics for the treatment of cancer. They aim to leverage their proprietary oncolytic viral immunotherapy technology to deliver targeted therapies that stimulate the patient*s immune system to attack and eliminate tumors. Through partnerships and collaborations, they seek to expand their reach and accelerate the development and delivery of innovative treatments.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 173.808 mill. $ - mill. $ -31.927 mill. 29 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 173.808 mill.


$ - mill.


$ -31.927 mill.

Employees Shares Outstanding P/E

-


29 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



RNA

$45.12

$35.0300 347.18%
Last 12 Months


RNA

$45.12

$35.0300 347.18%



Avidity Biosciences Inc

Avidity Biosciences Inc stock improved 347.18% over the past 12 months.


Avidity Biosciences Inc*s business model revolves around developing and commercializing potential therapeutics using its proprietary AOC platform, which enables the targeted delivery of drugs to specific cells in the body.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,935.005 mill. $ 10.870 mill. $ -228.681 mill. 87 mill. - Y/Y 58.67 %
Market Cap. Revenues TTM Net Income TTM

$ 3,935.005 mill.


$ 10.870 mill.


$ -228.681 mill.

Employees Shares Outstanding P/E

-


87 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 58.67 %


MRQ Y/Y - %



INVO

$0.74

$0.5650 322.86%
Last 12 Months


INVO

$0.74

$0.5650 322.86%



Invo Bioscience Inc

Invo Bioscience Inc stock improved 322.86% over the past 12 months.


Invo Bioscience Inc operates on a business model focused on developing and commercializing advanced medical devices in the field of reproductive health. Their flagship product, INVOcell, is a novel fertility treatment that allows fertilization and early embryo development to occur within the woman*s body. This innovative approach provides a more affordable and accessible option for couples seeking assisted reproductive technology.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2.813 mill. $ 4.249 mill. $ -7.080 mill. 4 mill. - Y/Y 352.92 %
Market Cap. Revenues TTM Net Income TTM

$ 2.813 mill.


$ 4.249 mill.


$ -7.080 mill.

Employees Shares Outstanding P/E

-


4 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 352.92 %


MRQ Y/Y - %



WGS

$31.83

$24.2300 318.82%
Last 12 Months


WGS

$31.83

$24.2300 318.82%



Genedx Holdings Corp

Genedx Holdings Corp shares increased 318.82% over the past 12 months.


Genedx Holdings Corp operates as a genetic testing company, offering molecular and biochemical testing services for various genetic disorders and diseases. The company generates revenue by providing testing services to medical professionals and institutions around the world, aiding in accurate diagnosis and treatment planning for patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 829.559 mill. $ 221.278 mill. $ -135.017 mill. 26 mill. - Y/Y 44.67 %
Market Cap. Revenues TTM Net Income TTM

$ 829.559 mill.


$ 221.278 mill.


$ -135.017 mill.

Employees Shares Outstanding P/E

-


26 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 44.67 %


MRQ Y/Y - %



SMMT

$8.785

$6.6350 308.60%
Last 12 Months


SMMT

$8.785

$6.6350 308.60%



Summit Therapeutics Inc

Summit Therapeutics Inc shares improved 308.60% over the past 12 months.


Summit Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of rare diseases. The company employs a research-driven business model, leveraging its proprietary technologies and expertise to identify and develop novel drugs targeting specific genetic mutations associated with these rare diseases. Summit Therapeutics Inc aims to bring its drug candidates through preclinical and clinical development stages and ultimately secure regulatory approval and commercialize them to benefit patients in need.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 6,165.183 mill. $ - mill. $ -116.025 mill. 702 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 6,165.183 mill.


$ - mill.


$ -116.025 mill.

Employees Shares Outstanding P/E

70


702 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



DRNK

$0.0004

$0.0003 300.00%
Last 12 Months


DRNK

$0.0004

$0.0003 300.00%



Noho, Inc.

Noho, Inc. stock went up 300.00% over the past 12 months.


Noho, Inc. operates based on a business model that is not clearly known or defined, as information about their model is unavailable beyond their website.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 0.007 mill. $ 1.177 mill. $ -5.733 mill. 18 mill. - Y/Y 65.54 %
Market Cap. Revenues TTM Net Income TTM

$ 0.007 mill.


$ 1.177 mill.


$ -5.733 mill.

Employees Shares Outstanding P/E

-


18 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 65.54 %


MRQ Y/Y - %



ADIL

$1.09

$0.8143 295.36%
Last 12 Months


ADIL

$1.09

$0.8143 295.36%



Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc stock increased 295.36% over the past 12 months.


Adial Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing medications for the treatment of alcohol use disorder. Their business model revolves around conducting clinical trials, obtaining regulatory approvals, and marketing their products to healthcare professionals and potential patients.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1.285 mill. $ - mill. $ -6.070 mill. 1 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1.285 mill.


$ - mill.


$ -6.070 mill.

Employees Shares Outstanding P/E

-


1 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SLN

$20.67

$15.3300 287.08%
Last 12 Months


SLN

$20.67

$15.3300 287.08%



Silence Therapeutics Plc

Silence Therapeutics Plc shares improved 287.08% over the past 12 months.


Silence Therapeutics Plc is a biomedical company that specializes in the discovery, development, and commercialization of innovative RNA-based therapeutics. They employ a business model focused on leveraging their proprietary technology to develop a pipeline of therapeutics targeting various diseases with high unmet medical needs. Through strategic partnerships and licensing agreements, they aim to deliver transformative RNA-based treatments to patients globally.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ - mill. $ 17.501 mill. $ -40.489 mill. - mill. - Y/Y 40.97 %
Market Cap. Revenues TTM Net Income TTM

$ - mill.


$ 17.501 mill.


$ -40.489 mill.

Employees Shares Outstanding P/E

-


- mill.


-

Revenue Growth Income Growth

MRQ Y/Y 40.97 %


MRQ Y/Y - %



PCSA

$1.63

$1.2036 282.27%
Last 12 Months


PCSA

$1.63

$1.2036 282.27%



Processa Pharmaceuticals Inc

Processa Pharmaceuticals Inc shares went up 282.27% over the past 12 months.


Processa Pharmaceuticals Inc is a biopharmaceutical company that operates by developing and commercializing innovative drug candidates for various medical conditions. They focus on advancing treatments through clinical trials, obtaining regulatory approvals, and partnering with other healthcare organizations for distribution and marketing.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 4.020 mill. $ - mill. $ -7.827 mill. 2 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 4.020 mill.


$ - mill.


$ -7.827 mill.

Employees Shares Outstanding P/E

-


2 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



DYN

$41.47

$30.4800 277.34%
Last 12 Months


DYN

$41.47

$30.4800 277.34%



Dyne Therapeutics Inc

Dyne Therapeutics Inc shares went up 277.34% over the past 12 months.


Dyne Therapeutics Inc is a biotechnology company that focuses on developing targeted therapies for patients with serious muscle diseases. They utilize their proprietary technology platform to deliver oligonucleotide therapeutics directly to muscle tissue, aiming to restore muscle function and improve overall patient outcomes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,522.130 mill. $ - mill. $ -208.126 mill. 61 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2,522.130 mill.


$ - mill.


$ -208.126 mill.

Employees Shares Outstanding P/E

1,679


61 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



APLT

$5.14

$3.7700 275.18%
Last 12 Months


APLT

$5.14

$3.7700 275.18%



Applied Therapeutics Inc

Applied Therapeutics Inc stock increased 275.18% over the past 12 months.


Applied Therapeutics Inc is a pharmaceutical company that focuses on developing and commercializing novel therapies to treat metabolic diseases. They employ a combination of in-house research and external collaborations to identify and advance potential drug candidates through clinical trials and regulatory approvals.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 644.140 mill. $ -0.477 mill. $ -193.564 mill. 125 mill. - Y/Y -98.22 %
Market Cap. Revenues TTM Net Income TTM

$ 644.140 mill.


$ -0.477 mill.


$ -193.564 mill.

Employees Shares Outstanding P/E

-


125 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -98.22 %


MRQ Y/Y - %



GCTK

$1.32

$0.9612 267.89%
Last 12 Months


GCTK

$1.32

$0.9612 267.89%



Glucotrack Inc

Glucotrack Inc stock improved 267.89% over the past 12 months.


Glucotrack Inc*s business model is focused on developing and marketing innovative non-invasive glucose monitoring devices for individuals with diabetes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 32.947 mill. $ - mill. $ 8.738 mill. 25 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 32.947 mill.


$ - mill.


$ 8.738 mill.

Employees Shares Outstanding P/E

-


25 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y 127.60 %



LEXX

$2.73

$1.9700 259.21%
Last 12 Months


LEXX

$2.73

$1.9700 259.21%



Lexaria Bioscience Corp

Lexaria Bioscience Corp shares increased 259.21% over the past 12 months.


Lexaria Bioscience Corp is a biotechnology company that focuses on enhancing the bioavailability and effectiveness of certain active compounds through its patented DehydraTECH technology. The company licenses its technology to third-party partners or collaborates with them to develop products in various sectors such as pharmaceuticals, nutraceuticals, and consumer packaged goods. Lexaria generates revenue through licensing fees, royalties from its partners, and potential product sales through its subsidiary, Lexaria Nicotine LLC.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 37.825 mill. $ -3.053 mill. $ -6.640 mill. 14 mill. - Y/Y -9.82 %
Market Cap. Revenues TTM Net Income TTM

$ 37.825 mill.


$ -3.053 mill.


$ -6.640 mill.

Employees Shares Outstanding P/E

-


14 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -9.82 %


MRQ Y/Y - %



JANX

$44.68

$32.2100 258.30%
Last 12 Months


JANX

$44.68

$32.2100 258.30%



Janux Therapeutics Inc

Janux Therapeutics Inc stock increased 258.30% over the past 12 months.


Janux Therapeutics Inc is a biotechnology company that focuses on developing and commercializing innovative cancer treatments. Their business model revolves around leveraging their expertise in immunotherapies and bispecific antibody platforms to create novel therapies that target tumor cells and activate the patient*s immune system. By partnering with pharmaceutical companies and conducting clinical trials, they aim to bring effective and personalized cancer treatments to market.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,042.262 mill. $ 8.467 mill. $ -62.600 mill. 46 mill. - Y/Y 38.83 %
Market Cap. Revenues TTM Net Income TTM

$ 2,042.262 mill.


$ 8.467 mill.


$ -62.600 mill.

Employees Shares Outstanding P/E

-


46 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 38.83 %


MRQ Y/Y - %



INSM

$75.97

$54.6800 256.83%
Last 12 Months


INSM

$75.97

$54.6800 256.83%



Insmed Inc

Insmed Inc shares improved 256.83% over the past 12 months.


Insmed Inc operates as a biopharmaceutical company focused on developing novel therapies for serious and rare diseases. The company*s business model revolves around discovering, developing, and commercializing innovative therapies to address significant unmet medical needs. Insmed Inc*s efforts primarily center around leveraging its expertise in biologics and advanced drug delivery technologies to improve the lives of patients with rare pulmonary diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 11,278.202 mill. $ 319.709 mill. $ -746.894 mill. 148 mill. - Y/Y 22.27 %
Market Cap. Revenues TTM Net Income TTM

$ 11,278.202 mill.


$ 319.709 mill.


$ -746.894 mill.

Employees Shares Outstanding P/E

400


148 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 22.27 %


MRQ Y/Y - %



ADMA

$13.36

$9.6000 255.32%
Last 12 Months


ADMA

$13.36

$9.6000 255.32%



Adma Biologics Inc

Adma Biologics Inc stock increased 255.32% over the past 12 months.


Adma Biologics Inc operates as a biopharmaceutical company focused on producing and commercializing specialty plasma-derived biologics for various medical conditions. The company*s business model revolves around collecting and fractionating plasma from qualified donors to manufacture and sell therapies for immune deficiency disorders, autoimmune diseases, and other indications. Adma Biologics markets its products directly to healthcare providers, hospitals, and other healthcare institutions while prioritizing patient safety and product quality.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 3,158.496 mill. $ 282.136 mill. $ -3.644 mill. 236 mill. - Y/Y 42.51 %
Market Cap. Revenues TTM Net Income TTM

$ 3,158.496 mill.


$ 282.136 mill.


$ -3.644 mill.

Employees Shares Outstanding P/E

256


236 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 42.51 %


MRQ Y/Y - %



KEQU

$50.85

$36.1900 246.86%
Last 12 Months


KEQU

$50.85

$36.1900 246.86%



Kewaunee Scientific Corporation

Kewaunee Scientific Corporation shares went up 246.86% over the past 12 months.


Kewaunee Scientific Corp operates as a global provider of laboratory furniture, fume hoods, and related equipment. Their business model revolves around designing, manufacturing, and installing these products for various industries including pharmaceutical, chemical, and healthcare. They aim to provide customized laboratory solutions while focusing on quality, safety, and compliance with industry standards.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 149.466 mill. $ 203.051 mill. $ 19.057 mill. 3 mill. 8.09 Y/Y 8.62 %
Market Cap. Revenues TTM Net Income TTM

$ 149.466 mill.


$ 203.051 mill.


$ 19.057 mill.

Employees Shares Outstanding P/E

1,357


3 mill.


8.09

Revenue Growth Income Growth

MRQ Y/Y 8.62 %


MRQ Y/Y 921.85 %



PRAX

$54.96

$38.6100 236.15%
Last 12 Months


PRAX

$54.96

$38.6100 236.15%



Praxis Precision Medicines Inc

Praxis Precision Medicines Inc stock increased 236.15% over the past 12 months.


Praxis Precision Medicines Inc*s business model revolves around developing precision medicines for the treatment of various central nervous system (CNS) disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 764.184 mill. $ 2.195 mill. $ -125.375 mill. 14 mill. - Y/Y -36.90 %
Market Cap. Revenues TTM Net Income TTM

$ 764.184 mill.


$ 2.195 mill.


$ -125.375 mill.

Employees Shares Outstanding P/E

-


14 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -36.90 %


MRQ Y/Y - %



VKTX

$50.9

$35.7000 234.87%
Last 12 Months


VKTX

$50.9

$35.7000 234.87%



Viking Therapeutics Inc

Viking Therapeutics Inc stock improved 234.87% over the past 12 months.


Viking Therapeutics Inc is a biopharmaceutical company focused on the development of innovative therapies for metabolic and endocrine disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 5,082.161 mill. $ - mill. $ -80.849 mill. 100 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 5,082.161 mill.


$ - mill.


$ -80.849 mill.

Employees Shares Outstanding P/E

11


100 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



TRIB

$3.3

$2.2801 223.56%
Last 12 Months


TRIB

$3.3

$2.2801 223.56%



Trinity Biotech Plc

Trinity Biotech Plc shares increased 223.56% over the past 12 months.


Trinity Biotech Plc*s business model is focused on developing, manufacturing, and marketing diagnostic products for clinical laboratories and point-of-care testing.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 25.242 mill. $ 56.832 mill. $ -36.868 mill. 8 mill. - Y/Y -24.00 %
Market Cap. Revenues TTM Net Income TTM

$ 25.242 mill.


$ 56.832 mill.


$ -36.868 mill.

Employees Shares Outstanding P/E

569


8 mill.


-

Revenue Growth Income Growth

MRQ Y/Y -24.00 %


MRQ Y/Y - %



TSHA

$2.14

$1.4700 219.40%
Last 12 Months


TSHA

$2.14

$1.4700 219.40%



Taysha Gene Therapies Inc

Taysha Gene Therapies Inc stock went up 219.40% over the past 12 months.


Taysha Gene Therapies Inc operates under a business model focused on developing and commercializing innovative genetic therapies to treat and potentially cure patients with rare monogenic diseases. Utilizing cutting-edge technologies, the company aims to bring transformative treatments to market in order to improve the lives of individuals suffering from these rare genetic disorders.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 269.000 mill. $ 14.349 mill. $ -215.030 mill. 126 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 269.000 mill.


$ 14.349 mill.


$ -215.030 mill.

Employees Shares Outstanding P/E

-


126 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



BLTE

$50.33

$34.4100 216.14%
Last 12 Months


BLTE

$50.33

$34.4100 216.14%



Belite Bio Inc

Belite Bio Inc stock increased 216.14% over the past 12 months.


Belite Bio Inc*s business model involves leveraging biotechnology to develop and commercialize innovative solutions for various industries. They focus on creating sustainable and environmentally friendly products by harnessing the power of natural biological processes.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 1,338.460 mill. $ - mill. $ -31.632 mill. 27 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 1,338.460 mill.


$ - mill.


$ -31.632 mill.

Employees Shares Outstanding P/E

-


27 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



MREO

$3.88

$2.6400 212.90%
Last 12 Months


MREO

$3.88

$2.6400 212.90%



Mereo Biopharma Group Plc

Mereo Biopharma Group Plc stock increased 212.90% over the past 12 months.


Mereo Biopharma Group Plc*s business model focuses on the development and commercialization of innovative therapeutics for rare diseases.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 2,211.341 mill. $ - mill. $ -34.196 mill. 570 mill. - Y/Y - %
Market Cap. Revenues TTM Net Income TTM

$ 2,211.341 mill.


$ - mill.


$ -34.196 mill.

Employees Shares Outstanding P/E

46


570 mill.


-

Revenue Growth Income Growth

MRQ Y/Y - %


MRQ Y/Y - %



SNDA

$29.41

$19.9500 210.89%
Last 12 Months


SNDA

$29.41

$19.9500 210.89%



Sonida Senior Living Inc

Sonida Senior Living Inc stock increased 210.89% over the past 12 months.


Sonida Senior Living Inc operates a business model focused on providing housing and care services for senior citizens. They aim to offer a comfortable and supportive environment for individuals requiring assisted living or memory care services. Their business model aims to cater to the unique needs of seniors, ensuring their wellbeing and overall quality of life.


Market Cap. Revenues TTM Net Income TTM Shares Outstanding P/E Revenue Growth
$ 310.628 mill. $ 260.687 mill. $ -24.227 mill. 11 mill. - Y/Y 8.64 %
Market Cap. Revenues TTM Net Income TTM

$ 310.628 mill.


$ 260.687 mill.


$ -24.227 mill.

Employees Shares Outstanding P/E

-


11 mill.


-

Revenue Growth Income Growth

MRQ Y/Y 8.64 %


MRQ Y/Y 8.93 %




 1 Day   Week  Current Month of July  30 Days 
Current Quarter Q3 of 2024  90 Days    Ytd    12 Months 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com